In the present study, we ascertained that the TRF strategy, hepatocyte-specific knockout of Per2, and the application of a ferroptotic inhibitor not only improved metabolic indices and liver enzymes but also reduced liver steatosis, inflammation, and fibrosis induced by HFHFD. Here, PER2 is linked to Hepatic steatosis.